ERBB2 and neoplasm: After eight treatment cycles with 120 mg of RC48, the tumor size decreased and stabilized.<h4>Conclusion</h4>This case report underscores the potential clinical value of RC48 as a promising treatment alternative for patients resistant to HER2 targeted therapies.